Picture loading failed.

Anti-PDCD1 therapeutic antibody (Pre-made Retifanlimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Retifanlimab, designated as INCMGA 0012, is a humanised IgG4k anti-PD-1 monoclonal antibody, being developed by Incyte Corporation, under a license from.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-480-1mg 1mg 3090
GMP-Bios-ab-480-10mg 10mg 21890
GMP-Bios-ab-480-100mg 100mg 148000
GMP-Bios-ab-480-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-PDCD1 therapeutic antibody (Pre-made Retifanlimab biosimilar,Whole mAb)
INN Name Retifanlimab
TargetPDCD1/PD-1
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa
Highest_Clin_Trial (Jan '20)Preregistration
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2019
Year Recommended2020
CompaniesMacroGenics;Incyte Corporation;ZAI Lab
Conditions Approvedna
Conditions ActiveGastic cancers;Oesophageal cancer;Anal cancer;Endometrial cancer;Merkel cell carcinoma;Solid tumours;Colorectal cancer;Acute myeloid leukaemia;Squamous cell cancer;Non-small cell lung cancer;Glioblastoma;Head and neck cancer;Liposarcoma;Pancreatic cancer;Penile cancer;Soft tissue sarcoma
Conditions DiscontinuedHaematological malignancies
Development Techna